AAAAAA

   
Results: 1-25 | 26-40
Results: 1-25/40
Ciguatera: clinical relevance of a marine neurotoxine
Authors: Ruprecht, K Rieckmann, P Giess, R
Citation: K. Ruprecht et al., Ciguatera: clinical relevance of a marine neurotoxine, DEUT MED WO, 126(28-29), 2001, pp. 812-814
Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data
Authors: Kristoferitsch, W Seeldrayers, P Kyriallis, K Brochet, B Confavreux, C Clanet, M Cesaro, P Defer, G Edan, G Lyon-Caen, O Pelletier, J Rumbach, L Roullet, E Vermersch, P Dengler, R Zschenderlein, R Storch-Hagenlocher, B Sailer, M Hohlfeld, R Kunze, KP Heesen, C Bamborschke, P Grunwald, F Hartung, HP Rieckmann, P DeKeyser, J Montalban, X Fernandez, U Arbizu, T Sandberg, M Kappos, L Bates, D Campbell, MJ Capildeo, R Compston, A McLellan, DL Wroe, S Young, C Clanet, M Hartung, HP Hohlfeld, R Kappos, L Radue, EW Rieckmann, P Sandberg, M Polman, C Kesselring, J Thompson, A Wekerle, H Whitehead, J Bains, H Butler, E Kooijmans-Coutinho, M McAllister, A Simonian, N White, K Anderson, D Liddiard, S Keane, R
Citation: W. Kristoferitsch et al., Double-blind randomized multicenter dose-comparison study of interferon-beta-1a (AVONEX): rationale, design and baseline data, MULT SCLER, 7(3), 2001, pp. 179-183
Neuritis nervi optici
Authors: Kiefer, G Rieckmann, P
Citation: G. Kiefer et P. Rieckmann, Neuritis nervi optici, OPHTHALMOLO, 98(3), 2001, pp. 310-318
Early treatment of multiple sclerosis and its accompanying economic effects on public health
Authors: Rieckmann, P
Citation: P. Rieckmann, Early treatment of multiple sclerosis and its accompanying economic effects on public health, MED KLIN, 96, 2001, pp. 17-21
Reduction of Menkes mRNA and copper in leukocytes of patients with primaryadult-onset dystonia
Authors: Kruse, N Berg, D Francis, MJ Naumann, M Rausch, WD Reiners, K Rieckmann, P Weishaupt, A Becker, G
Citation: N. Kruse et al., Reduction of Menkes mRNA and copper in leukocytes of patients with primaryadult-onset dystonia, ANN NEUROL, 49(3), 2001, pp. 405-408
Multiple sclerosis: Critical discussion of controversial and complementarytherapies based on current pathogenetic hypotheses
Authors: Weilbach, FX Rieckmann, P Gold, R Toyka, KV
Citation: Fx. Weilbach et al., Multiple sclerosis: Critical discussion of controversial and complementarytherapies based on current pathogenetic hypotheses, AKT NEUROL, 28(1), 2001, pp. 31-38
Influenza vaccination in MS - Absence of T-cell response against white matter proteins
Authors: Moriabadi, NF Niewiesk, S Kruse, N Jung, S Weissbrich, B ter Meulen, V Toyka, KV Rieckmann, P
Citation: Nf. Moriabadi et al., Influenza vaccination in MS - Absence of T-cell response against white matter proteins, NEUROLOGY, 56(7), 2001, pp. 938-943
PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
Authors: Francis, G Hughes, R King, J Mitchell, P Joubert, J McLeod, J Parker, G Pollard, J Sindic, CJM Duprez, T Medaer, R Broeckx, J Vanroose, E Carton, H Wilms, G Rice, G Ebers, G Lee, DH Freedman, M Nelson, R Rabinovitch, H Christie, S Avruch, L Oger, J Paty, DW Li, D Wikstrom, J Salonen, OLM Panelius, M Eralinna, J Sonninen, P Rieckmann, P Hahn, D Flachenecker, P Hartung, HP Uitdehaag, B Bertelsmann, FW Barkhof, F Hommes, OR Jongen, PJH Van Doorn, PA Tanghe, HLG Sandberg-Wollheim, M Larsson, EM Lonntoft, M Sallerfors, S Kappos, L Lienert, C Radu, EW Chofflon, M Roth, S Castillo, V Schwieger, AF Hughes, RAC Clews, AM Bingham, JB Barnes, D Clifton, AG Stoy, N Bates, D Coulthard, A Blumhardt, LD Evans, SM Jaspan, T Palace, J Newsom-Davis, JM Byrne, JV Quaghebeur, G Li, DKB Paty, DW Zhao, GJ Riddehough, A Rhodes, B
Citation: G. Francis et al., PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS, NEUROLOGY, 56(12), 2001, pp. 1628-1636
Treatment of multiple sclerosis with recombinant interferon-beta preparations. Views on pharmocology and dosage
Authors: Maurer, M Gold, R Toyka, KV Rieckmann, P
Citation: M. Maurer et al., Treatment of multiple sclerosis with recombinant interferon-beta preparations. Views on pharmocology and dosage, NERVENARZT, 72(2), 2001, pp. 108-116
Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement
Authors: Buttner, U Chofflon, M Hess, K Kappos, L Kesselring, J Ludin, HP Schluep, M Vaney, C Baumhackl, U Berger, T Deisenhammer, F Freimuller, M Hartung, HP Kollegger, H Kristoferitsch, W Lassmann, H Markut, H Vass, K Altenkirch, H Boese, J Gass, A Gehlen, W Goebels, N Haas, J Haferkamp, G Heidenreich, F Heitmann, R Hemmer, B Hohlfeld, R Janzen, RWC Jugelt, E Kolmel, W Konig, N Kowitzsch, K Manegold, U Melms, A Mertin, J Petereit, HF Pette, M Pohlau, D Poser, S Sailer, M Schmidt, S Schock, G Schulz, M Seidel, D Stangel, M Stark, E Stoll, G Weinrich, W Wietholter, H Zettl, UK Zipp, F Zschenderlein, R Bayas, A Chan, A Flachenecker, P Gold, R Grauer, O Jung, S Kallmann, B Leussink, V Maurer, M Rieckmann, P Toyka, KV Weilbach, FX
Citation: U. Buttner et al., Escalating immunomodulatory therapy of multiple sclerosis - 1. Supplement, NERVENARZT, 72(2), 2001, pp. 150-157
Genetic polymorphism of the tumor necrosis factor (TNF)-alpha promoter region in families with localized early-onset periodontitis
Authors: Shapira, L Stabholz, A Rieckmann, P Kruse, N
Citation: L. Shapira et al., Genetic polymorphism of the tumor necrosis factor (TNF)-alpha promoter region in families with localized early-onset periodontitis, J PERIOD RE, 36(3), 2001, pp. 183-186
Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules
Authors: Hummel, V Kallmann, BA Wagner, S Fuller, T Bayas, A Tonn, JC Benveniste, EN Toyka, KV Rieckmann, P
Citation: V. Hummel et al., Production of MMPs in human cerebral endothelial cells and their role in shedding adhesion molecules, J NE EXP NE, 60(4), 2001, pp. 320-327
Effects of oncostatin M on human cerebral endothelial cells and expressionin inflammatory brain lesions
Authors: Ruprecht, K Kuhlmann, T Seif, F Hummel, V Kruse, N Bruck, W Rieckmann, P
Citation: K. Ruprecht et al., Effects of oncostatin M on human cerebral endothelial cells and expressionin inflammatory brain lesions, J NE EXP NE, 60(11), 2001, pp. 1087-1098
Characterization of early immunological responses in primary cultures of differentially activated human peripheral mononuclear cells
Authors: Kruse, N Moriabadi, NF Toyka, KV Rieckmann, P
Citation: N. Kruse et al., Characterization of early immunological responses in primary cultures of differentially activated human peripheral mononuclear cells, J IMMUNOL M, 247(1-2), 2001, pp. 131-139
A quality network model for the dolly care of multiple sclerosis
Authors: Blumhardt, LD Vermeij, BJD Amato, M Andersen, O Edan, G Fernandez, O Filippi, M Haas, J Hommes, OR Rieckmann, P
Citation: Ld. Blumhardt et al., A quality network model for the dolly care of multiple sclerosis, MULT SCLER, 6(4), 2000, pp. 231-236
Lesion pattern in patients with multiple sclerosis and depression
Authors: Berg, D Supprian, T Thomae, J Warmuth-Metz, M Horowski, A Zeiler, B Magnus, T Rieckmann, P Becker, G
Citation: D. Berg et al., Lesion pattern in patients with multiple sclerosis and depression, MULT SCLER, 6(3), 2000, pp. 156-162
Relapsing-remitting multiple sclerosis - What is the potential for combination therapy?
Authors: Maurer, M Rieckmann, P
Citation: M. Maurer et P. Rieckmann, Relapsing-remitting multiple sclerosis - What is the potential for combination therapy?, BIODRUGS, 13(3), 2000, pp. 149-158
Multiple sclerosis and sports
Authors: Bayas, A Rieckmann, P
Citation: A. Bayas et P. Rieckmann, Multiple sclerosis and sports, AKT NEUROL, 27(6), 2000, pp. 258-261
Neurology and sports
Authors: Reimers, CD Rieckmann, P
Citation: Cd. Reimers et P. Rieckmann, Neurology and sports, AKT NEUROL, 27(5), 2000, pp. 193-196
Genetic variation at position-1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis
Authors: Maurer, M Kruse, N Giess, R Toyka, KV Rieckmann, P
Citation: M. Maurer et al., Genetic variation at position-1082 of the interleukin 10 (IL10) promotor and the outcome of multiple sclerosis, J NEUROIMM, 104(1), 2000, pp. 98-100
Managing the adverse effects of interferon-beta therapy in multiple sclerosis
Authors: Bayas, A Rieckmann, P
Citation: A. Bayas et P. Rieckmann, Managing the adverse effects of interferon-beta therapy in multiple sclerosis, DRUG SAFETY, 22(2), 2000, pp. 149-159
Effect of interferon beta on human myelin basic protein-specific T-cell lines: Comparison of IFN beta-1a and IFN beta-1b - Reply
Authors: Weber, F Rieckmann, P
Citation: F. Weber et P. Rieckmann, Effect of interferon beta on human myelin basic protein-specific T-cell lines: Comparison of IFN beta-1a and IFN beta-1b - Reply, NEUROLOGY, 55(2), 2000, pp. 322-323
Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis
Authors: Cursiefen, S Flachenecker, P Toyka, KV Rieckmann, P
Citation: S. Cursiefen et al., Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis, EUR NEUROL, 43(3), 2000, pp. 186-187
Variations in cytokine mRNA expression during normal human pregnancy
Authors: Kruse, N Greif, M Moriabadi, NF Marx, L Toyka, KV Rieckmann, P
Citation: N. Kruse et al., Variations in cytokine mRNA expression during normal human pregnancy, CLIN EXP IM, 119(2), 2000, pp. 317-322
Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1
Authors: Kallmann, BA Hummel, V Lindenlaub, T Ruprecht, K Toyka, KV Rieckmann, P
Citation: Ba. Kallmann et al., Cytokine-induced modulation of cellular adhesion to human cerebral endothelial cells is mediated by soluble vascular cell adhesion molecule-1, BRAIN, 123, 2000, pp. 687-697
Risultati: 1-25 | 26-40